July 1, 2013

The Food and Drug Administration has approved a drug made by Sunovion and Dainippon Sumitomo Pharma Co. for bipolar disorder, Sunovion said.

July 1, 2013

The Food and Drug Administration has declined to approve a sleeping pill made by Merck & Co., citing issues with dosage.

June 26, 2013

Teva Pharmaceutical Industries and Mylan have launched generic versions of Pfizer's Viagra in nearly a dozen European countries, the two companies said.

June 18, 2013

Avella Specialty Pharmacy will be included in the limited-distribution network for a cancer drug made by Genentech, Avella said Tuesday.

June 12, 2013

Meijer will open two new stores in northern Indiana, the mass merchandise retailer said.

June 12, 2013

Pfizer will receive more than $2 billion from Teva Pharmaceutical Industries and Sun Pharmaceutical Industries to settle a case concerning a gastroesophageal reflux disease drug.

June 11, 2013

Misperceptions and stereotypes about opioid dependence that may affect how it's treated have persisted among the general public and physicians despite increased attention devoted to the issue, according to a new survey.

June 10, 2013

Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

June 7, 2013

The May/June 2013 Skin/itch Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of AmLactin Moisturizing Body Lotion, CeraVe Renewing SA Cream, Olay Advanced Healing, Curel Itch Defense, Vaseline Intensive Rescue, Tecnu Extreme, Benadryl ExtraStrength Spray and Allegra Anti-itch Cream.

June 6, 2013

The Food and Drug Administration has approved a drug made by Celgene for treating a type of cancer.

June 4, 2013

Johnson & Johnson division McNeil Consumer Healthcare has launched a new marketing campaign around the allergy medication Zyrtec, according to published reports.

May 30, 2013

The year is only halfway done, but 2013 is already proving to be a year of particular importance for generic drugs as the industry awaits two important decisions from the Supreme Court and continues to wait for federal biosimilar regulations while fending off efforts to limit the scope of their use at the state level.

May 22, 2013

The Food and Drug Administration has approved a generic heart disease drug made by Sandoz, the company said.

May 17, 2013

A Food and Drug Administration panel will consider whether to recommend approval for an experimental painkiller in July, the drug's developer said Friday.

May 17, 2013

Mylan has launched a generic drug for treating cholesterol, the company said.

May 15, 2013

The Food and Drug Administration has approved a drug for a type of lung cancer.

May 13, 2013

A ruling by the Food and Drug Administration means that generic versions of an opioid painkiller made by Endo Pharmaceuticals can stay on the market, drawing criticism from the drug maker.

May 8, 2013

There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.

May 6, 2013

Pfizer is attempting to stem the rise of counterfeit medicines by selling one of its most popular drugs — and one of the most popular targets for counterfeiters — online.

May 6, 2013

The Food and Drug Administration has approved a drug for HIV in infants and toddlers.

May 6, 2013

The Food and Drug Administration has approved a new drug made by Merck for treating high cholesterol, the drug maker said.

April 30, 2013

The Food and Drug Administration has approved two generic drugs made by Aurobindo Pharma, the drug maker said.

April 30, 2013

The Food and Drug Administration declined to approve two drugs for HIV made by Gilead Sciences for which the company was seeking approval for use as part of treatment regimens.

April 26, 2013

Generic drug maker Actavis is settling a patent-infringement suit with Purdue Pharma concerning the opioid painkiller OxyContin, Actavis said, saying it expected to make more than $100 million in the deal between 2014 and 2015.